- Home
- SBFG vs EQ Comparison
SBFG vs EQ Comparison
Compare SBFG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | EQ |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 157.4M |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SBFG | EQ |
|---|---|---|
| Price | $26.80 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 13.4K | ★ 504.8K |
| Earning Date | 04-23-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 27.33 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.16 | $0.76 |
| 52 Week High | $28.38 | $3.54 |
Technical Indicators
Market Signals| Indicator | SBFG | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 46.03 |
| Support Level | $20.94 | $1.68 |
| Resistance Level | $27.35 | $2.61 |
| Average True Range (ATR) | 0.83 | 0.19 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 31.82 | 53.39 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.